生物技术公司Genprex宣布，其创新疗法组合——Reqorsa®基因疗法与PD-1抗体联合用于癌症治疗的方案，已正式获得以色列专利局颁发的专利授权。这一突破性进展进一步巩固了该公司在肿瘤免疫治疗领域的技术壁垒。
该专利覆盖了基因治疗载体与免疫检查点抑制剂协同作用的核心技术，为开发新型癌症联合疗法提供了知识产权保护。通过将基因疗法与免疫疗法相结合，该方案有望激活患者自身的抗肿瘤免疫反应，提升晚期癌症患者的生存希望。
此次专利授权标志着Genprex在全球化知识产权布局中迈出关键一步，为其未来在中东地区的临床推进和商业合作奠定基础。公司表示将继续推进该联合疗法的临床研究，探索其在肺癌、胰腺癌等难治性肿瘤中的应用潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.